[AMAG] AMAG Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 35.8 Change: 1 (2.87%)
Ext. hours: Change: 0 (0%)

chart AMAG

Refresh chart

Description: AMAG Pharmaceuticals, Inc. develops and commercializes specialty pharmaceutical products. The company markets Feraheme (ferumoxytol) injection for use as an intravenous (IV) iron replacement therapy for the treatment of iron deficiency anemia in adult patients with chronic kidney disease; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. It markets Feraheme in the United States and Canada; and as Rienso in the European Union. The company sells Feraheme to authorized wholesalers and specialty distributors. AMAG Pharmaceuticals, Inc. has a license, development, and commercialization agreement with Takeda Pharmaceutical Company Limited to develop and commercialize Feraheme/Rienso as a therapeutic agent in Europe, certain Asia-Pacific countries, the Commonwealth of Independent States, Canada, India, and Turkey; and collaboration and exclusive license agreement with 3SBio for the development and commercialization of Feraheme as an IV iron rep

Fundamental Ratios
Shares Outstanding EPS1.11 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 385.93% Sales Growth - Q/Q38.41% P/E14.77
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA11.63% ROE26.74% ROI15.98%
Current Ratio1.71 Quick Ratio1.61 Long Term Debt/Equity1.51 Debt Ratio0.45
Gross Margin81.03% Operating Margin31.1% Net Profit Margin65.25% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities183.64 M Cash From Investing Activities-284.74 M Cash From Operating Activities71.69 M Gross Profit104.2 M
Net Profit33.26 M Operating Profit61.12 M Total Assets1.64 B Total Current Assets555.48 M
Total Current Liabilities323.97 M Total Debt483.2 M Total Liabilities926.3 M Total Revenue123.88 M
Technical Data
High 52 week25.55 Low 52 week12.3 Last close22.35 Last change1.36%
RSI53.15 Average true range0.88 Beta0.72 Volume768.3 K
Simple moving average 20 days3.57% Simple moving average 50 days-0.11% Simple moving average 200 days21.31%
Performance Data
Performance Week2.29% Performance Month12.59% Performance Quart7.97% Performance Half55.75%
Performance Year14.91% Performance Year-to-date68.68% Volatility daily2% Volatility weekly4.46%
Volatility monthly9.15% Volatility yearly31.68% Relative Volume235.39% Average Volume752.56 K
New High New Low

News

2019-03-20 08:00:00 | March of Dimes and AMAG Pharmaceuticals, Inc., Announce First Joint Supportive Pregnancy Care Program

2019-03-18 12:43:33 | New Doubt on Treatment to Prevent Preterm Birth

2019-03-13 10:46:02 | Biotech Stock Roundup: REGN Gets FDA Nod for Dupixent & Other Pipeline News

2019-03-11 10:35:02 | AMAG's Stock Down as Pregnancy Drug Fails in PROLONG Study

2019-03-09 09:31:02 | Why Is AMAG Pharmaceuticals AMAG Down 24.5% Since Last Earnings Report?

2019-03-08 11:26:41 | Amag's shares fall after $323M pregnancy drug fails in post-approval trial

2019-03-08 09:00:00 | AMAG Pharmaceuticals stock down 6% after latest trial of Makena fails to meet primary endpoints

2019-03-08 08:00:00 | AMAG Pharmaceuticals Announces Topline Results From the PROLONG Trial Evaluating Makena® hydroxyprogesterone caproate injection

2019-03-07 08:00:00 | AMAG Pharmaceuticals Presents New Data on Bremelanotide and Hypoactive Sexual Desire Disorder at the ISSWSH/ISSM Joint Meeting

2019-03-05 08:00:00 | AMAG Pharmaceuticals to Present at Upcoming Investor Conferences

2019-03-01 15:48:25 | AMAG Pharmaceuticals Inc AMAG Files 10-K for the Fiscal Year Ended on December 31, 2018

2019-02-28 12:31:49 | Antares Pharma Inc ATRS Q4 2018 Earnings Conference Call Transcript

2019-02-19 08:00:00 | AMAG Pharmaceuticals to Present at Leerink Partners Global Healthcare Conference

2019-02-08 20:59:18 | AMAG Pharmaceuticals AMAG Q4 2018 Earnings Conference Call Transcript

2019-02-08 10:00:03 | AMAG Q4 Loss Narrower Than Expected, Revenues Lag Estimates

2019-02-08 07:34:29 | Edited Transcript of AMAG earnings conference call or presentation 7-Feb-19 1:00pm GMT

2019-02-07 08:55:01 | AMAG Pharmaceuticals AMAG Reports Q4 Loss, Misses Revenue Estimates

2019-02-07 07:57:27 | AMAG Pharmaceuticals: 4Q Earnings Snapshot

2019-02-07 07:00:00 | AMAG Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Company Update

2019-01-30 08:00:00 | AMAG Pharmaceuticals to Host Fourth Quarter and Full Year 2018 Financial Results Conference Call and Webcast on Thursday, February 7, 2019 at 8:00 a.m. ET

2019-01-17 08:00:00 | AMAG Pharmaceuticals Completes Acquisition of Perosphere Pharmaceuticals

2019-01-17 07:30:00 | Research Report Identifies Edison International, MPLX LP, Moody's, AMAG Pharmaceuticals, Cross Country Healthcare, and New Mountain Finance with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

2019-01-15 08:00:00 | AMAG Pharmaceuticals Appoints Christine Moulton Clemson, Ph.D., M.S.C.I. as Vice President of Medical Affairs

2019-01-07 07:00:00 | AMAG Pharmaceuticals Announces Preliminary 2018 Financial Results and Provides 2019 Financial Guidance

2018-12-27 13:55:02 | Spectrum Pharmaceuticals: Earnings Trends and Recent Developments

2018-12-27 12:25:02 | Spectrum Pharmaceuticals: Financial Overview in December

2018-12-27 08:25:01 | AMAG Up Nearly 10% in a Year on Label Expansion, Acquisitions

2018-12-19 08:00:00 | AMAG Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference

2018-12-14 10:25:03 | AMAG to Acquire Ciraparantag Maker Perosphere Pharmaceuticals

2018-12-13 06:30:00 | AMAG Pharmaceuticals Enters Into Definitive Merger Agreement to Acquire Perosphere Pharmaceuticals

2018-12-04 12:06:36 | Estimating The Fair Value Of AMAG Pharmaceuticals Inc NASDAQ:AMAG

2018-12-03 08:00:00 | Study of Feraheme demonstrates Improvements in Fatigue and Quality Of Life in Iron Deficiency Anemia Patients

2018-11-29 12:50:19 | Paul Tudor Jones Continues to Buy Apple, Alibaba

2018-11-29 08:00:00 | AMAG Pharmaceuticals Awards Four Grants to Further Research in Preterm Birth and Preeclampsia

2018-11-26 17:37:10 | AMAG's Label Expansion of Lead Products Raises Share Price

2018-11-08 08:10:00 | Detailed Research: Economic Perspectives on KB Home, Lennox International, CorVel, Acorda Therapeutics, PROS, and AMAG Pharmaceuticals — What Drives Growth in Today's Competitive Landscape

2018-11-06 08:00:00 | AMAG Pharmaceuticals to Present at Upcoming Investor Conferences

2018-11-02 17:11:09 | AMAG Posts Wider-Than-Expected Q3 Loss, Beats on Revenues

2018-11-01 17:08:00 | Here's Why AMAG Pharmaceuticals Tumbled 12.7% Today

2018-11-01 14:29:57 | Edited Transcript of AMAG earnings conference call or presentation 1-Nov-18 12:00pm GMT

2018-11-01 12:12:22 | AMAG Pharmaceuticals Inc AMAG Q3 2018 Earnings Conference Call Transcript

2018-11-01 12:10:04 | AMAG Pharmaceuticals AMAG Reports Q3 Loss, Tops Revenue Estimates

2018-11-01 10:42:38 | AMAG Pharmaceuticals: 3Q Earnings Snapshot

2018-11-01 07:00:00 | AMAG Pharmaceuticals Announces Third Quarter 2018 Financial Results and Provides Corporate Update

2018-10-29 09:02:01 | The Zacks Analyst Blog Highlights: Allergan, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and AMAG Pharmaceuticals

2018-10-26 16:02:08 | 5 Drug/Biotech Stocks Likely to Beat Estimates in Q3 Earnings

2018-10-25 10:33:02 | AMAG Pharmaceuticals AMAG Q3 Earnings Preview: What to Watch Ahead of the Release

2018-10-25 08:00:00 | AMAG Pharmaceuticals to Host Third Quarter 2018 Financial Results Conference Call and Webcast on Thursday, November 1, 2018 at 8:00 a.m. ET

2018-10-17 08:15:00 | Report: Exploring Fundamental Drivers Behind CURO Group, BiondVax Pharmaceuticals, AMAG Pharmaceuticals, AcelRx Pharmaceuticals, Ballard Power, and Rhythm Pharmaceuticals — New Horizons, Emerging Trends, and Upcoming Developments

2018-10-09 08:51:12 | Is the Options Market Predicting a Spike in AMAG Pharmaceuticals AMAG Stock?